0000000000090894
AUTHOR
Lucia Tozzi
Vita e morte dei suburbia
Architetti, ancora uno sforzo
Ritorno a Milano - intervista ad Alessandro Pasquarelli, CEO di Euromilano
Congreso UIA : Comunicar la arquitectura
Editoriale - Architettura e tempo
Spel der vervreemding
Architettura Popolare Cinese
Sul futuro delle città
Vita e morte dei suburbia
Il contrario di Dubai
La casa ai tempi della crisi - intervista a Giovanni Caudo
CAPITALI D'ORIENTE. L'ESPLOSIONE
Vivere il cambiamento - intervista a Sandra Bonfiglioli
La città del futuro
Torino Geodesign
La città che sale (e scende)- Dubai tra passato e futuro
Editoriale - Milano
Wilkommen in der Immobilienwuste!
I primi workshop Geodesign
La mia battaglia in rete - intervista a Edoardo Salzano
La città densa
An Interview with Giorgio Grassi
In January 2007, Lucia Tozzi visited Giorgio Grassi's office in Milan. Their conversation touched on Grassi's recent work on Leon Battista Alberti, which is examined here in the context of Grassi's obliquely expressed views on contemporary architecture and the cult of personality. As perhaps the most intellectually rigorous and formally consistent Rationalist architect of his generation, Grassi's work and thinking retain a hermetic aspect, but one notable for its philosophical self-questioning and underlying political commitment. Copyright © 2007 John Wiley & Sons, Ltd.
Therapeutic sequences in patients with grade 1−2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group
Purpose: Many different treatments are suggested by guidelines to treat grade 1−2 (G1−G2) neuroendocrine tumors (NET). However, a precise therapeutic algorithm has not yet been established. This study aims at identifying and comparing the main therapeutic sequences in G1−G2 NET. Methods: A retrospective observational Italian multicenter study was designed to collect data on therapeutic sequences in NET. Median progression-free survival (PFS) was compared between therapeutic sequences, as well as the number and grade of side effects and the rate of dose reduction/treatment discontinuation. Results: Among 1182 patients with neuroendocrine neoplasia included in the ELIOS database, 131 G1–G2 ga…